3/3
02:33 am
smmt
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment [Yahoo! Finance]
3/2
05:00 pm
smmt
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Medium
Report
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
3/2
09:46 am
smmt
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab [Yahoo! Finance]
Low
Report
Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab [Yahoo! Finance]
2/26
06:45 pm
smmt
Summit Therapeutics to Present at Upcoming Investor Conferences
Medium
Report
Summit Therapeutics to Present at Upcoming Investor Conferences
2/24
08:24 pm
smmt
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Low
Report
Summit Therapeutics Inc (SMMT) Q4 2025 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
2/24
12:51 pm
smmt
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Summit Therapeutics Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/24
08:02 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its price target lowered by analysts at HC Wainwright from $40.00 to $30.00. They now have a "buy" rating on the stock.
2/24
07:01 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
2/24
04:22 am
smmt
Summit Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Summit Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/24
04:00 am
smmt
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript [Seeking Alpha]
2/23
04:48 pm
smmt
Summit Therapeutics Non-GAAP EPS of -$0.14 misses by $0.12 [Seeking Alpha]
Low
Report
Summit Therapeutics Non-GAAP EPS of -$0.14 misses by $0.12 [Seeking Alpha]
2/23
04:05 pm
smmt
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
Low
Report
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
2/17
05:30 pm
smmt
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 [Yahoo! Finance]
Low
Report
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026 [Yahoo! Finance]
2/17
05:05 pm
smmt
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
Medium
Report
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
2/16
12:38 pm
smmt
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough [Yahoo! Finance]
Medium
Report
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough [Yahoo! Finance]
2/12
07:07 am
smmt
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? [Yahoo! Finance]
Medium
Report
Is Summit Therapeutics Inc. (SMMT) One of the Most Oversold NASDAQ Stocks to Invest In? [Yahoo! Finance]
2/8
01:36 pm
smmt
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately [Yahoo! Finance]
Low
Report
Is Summit Therapeutics (SMMT) Pricing Reflecting Its Recent Share Price Pullback Accurately [Yahoo! Finance]
2/6
06:32 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
2/2
08:05 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/30
06:40 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
1/30
04:30 pm
smmt
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/30
09:25 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $40.00 price target on the stock.
1/30
08:02 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
1/30
07:36 am
smmt
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]
Medium
Report
Summit Therapeutics: PDUFA Coming, But Is It Good Enough? (Rating Upgrade) [Seeking Alpha]
1/29
07:30 am
smmt
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy
Medium
Report
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy